GlassScriptPhysician profile
Stuart Rhein
NPI 1932294329
$1,230.90
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $291 · 2022: $15.31.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $347.77 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $224.32 | 2019-2020 | |
| Genzyme Corporation | $188.63 | 2019-2020 | |
| Kaleo, INC. | $99.37 | 2019 | |
| Circassia INC. | $58.63 | 2019-2020 | |
| Optinose US, INC. | $41.62 | 2019 | |
| Shire North American Group INC | $40.75 | 2019 | |
| Csl Behring | $31.09 | 2019 | |
| Pfizer INC. | $29.63 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.78 | 2019 | |
| Phadia US INC. | $23.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.15 | 2019 | |
| Octapharma USA, INC. | $22.08 | 2020 | |
| Genentech USA, INC. | $17.61 | 2020 | |
| Alk-Abello, INC | $16.13 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $15.31 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Rhein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.